Li, M., Chiang, Y. L., Lyssiotis, C. A., Teater, M. R., Hong, J. Y., Shen, H., Wang, L., Hu, J., Jing, H., Chen, Z., Jain, N., Duy, C., Mistry, S. J., Cerchietti, L., Cross, J. R., Cantley, L. C., Green, M. R., Lin, H., & Melnick, A. M. (2019). Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer cell, 35(6), 916–931.e9. https://doi.org/10.1016/j.ccell.2019.05.002
Diffuse large B cell lymphomas (DLBCLs) are genetically heterogeneous and highly proliferative neoplasms derived from germinal center (GC) B cells. Here, we show that DLBCLs are dependent on mitochondrial lysine deacetylase SIRT3 for proliferation, survival, self-renewal, and tumor growth in vivo regardless of disease subtype and genetics. SIRT3 knockout attenuated B cell lymphomagenesis in VavP-Bcl2 mice without affecting normal GC formation. Mechanistically, SIRT3 depletion impaired glutamine flux to the TCA cycle via glutamate dehydrogenase and reduction in acetyl-CoA pools, which in turn induce autophagy and cell death. We developed a mitochondrial-targeted class I sirtuin inhibitor, YC8-02, which phenocopied the effects of SIRT3 depletion and killed DLBCL cells. SIRT3 is thus a metabolic non-oncogene addiction and therapeutic target for DLBCLs.
Journal: Cancer Cell PMID: 31185214 DOI: 10.1016/j.ccell.2019.05.002